PRME (Prime Medicine) Moat Score: 6/10 (As of Jun. 26, 2026)


PRME Prime Medicine Inc PRME
25 GF Score
Price $3.18
! 4 Warning Signs
View Full Analysis

What is Prime Medicine Moat Score?

Prime Medicine PRME +2.09% 25 Moat Score is 6 as of Jun. 26, 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,404 Biotechnology companies, Prime Medicine ranks better than 98.93% on this metric.

Prime Medicine has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Prime Medicine has Narrow Moat: Prime Medicine Inc possesses a strong narrow moat with valuable intellectual property and patents in the biotech sector. Its R&D capabilities and innovation are significant, but it lacks the market dominance and regulatory barriers to be classified as a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Prime Medicine might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Prime Medicine  (NAS:PRME) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Prime Medicine Moat Score Related Terms

PRME vs IMMX, SGP, ACRS: Moat Score Comparison

For the Biotechnology subindustry, Prime Medicine's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prime Medicine Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prime Medicine's Moat Score distribution charts can be found below:

* The bar in red indicates where Prime Medicine's Moat Score falls into.


PRME
25GF Score
Prime Medicine Inc PRME
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Prime Medicine (PRME) has a Moat Score of 6 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Prime Medicine ranks #15 out of 1404 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Prime Medicine's Moat Score too high?
Prime Medicine's current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. Prime Medicine's value of 6 is 200% above this industry median. Based on the distribution chart, Prime Medicine ranks #15 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's Moat Score compare to IMMX and SGP?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #15 out of 1404 companies for Moat Score. This places Prime Medicine in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Prime Medicine's value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prime Medicine's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prime Medicine's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current Moat Score of 6. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. Prime Medicine's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Prime Medicine (PRME), the current Moat Score is 6 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prime Medicine Business Description

Address 60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score

Get the complete analysis for PRME

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price